Drug Profile
Botulinum toxin A - Lipella Pharmaceuticals
Alternative Names: Lipo-BoNT; Liposomal botulinum toxin A - Lipella Pharmaceuticals; Liposome encapsulated BoNT-A - Lipella; Lipotoxin - Lipella; LP-09; OnabotulinumtoxinA - LipellaLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Lipella Pharmaceuticals
- Developer Buddhist Tzu Chi General Hospital; Lipella Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Interstitial cystitis; Overactive bladder
Most Recent Events
- 23 Mar 2017 Phase-II development for Overactive bladder is ongoing in Taiwan
- 23 Mar 2017 Lipella's botulinum toxin-A licensed to an unknown company worldwide (Lipella Pharmaceuticals website, March 2017)
- 01 Feb 2017 Buddhist Tzu Chi General Hospital completes a phase II trial in Interstitial cystitis (In adults, In the elderly) in Taiwan (Intravesicular) (NCT02247557)